Skip to content

PagerDuty

US · PD #3120 by market cap Listed 2019
14.63 -1.15 -7.29%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • Rating change
    A Quick Look at Today's Ratings for PagerDuty(PD.US), With a Forecast Between $9.5 to $15
    Market Newswire · 2026/8/29
  • Rating change
    Kelun Biotech (6990.HK): Outstanding first-line data for PD-L1-negative patients; overseas commercialization imminent.
    Citic Securities · 2026/10/29
  • Rating change
    Truist Financial Maintains PagerDuty(PD.US) With Buy Rating, Raises Target Price to $13
    Market Newswire · 2026/8/20
  • Rating change
    RBC Capital Maintains PagerDuty(PD.US) With Hold Rating, Raises Target Price to $12
    Market Newswire · 2026/8/14
  • Henlius (02696) H Drug at ESMO 2026: U.S. Bridging Study to Be Presented Orally; New Evidence Added for Global First Anti-PD-1 Monoclonal Antibody in First-Line Lung Cancer Treatment
    Zhitong Finance · 2026/10/19
  • Rating change
    BofA Securities Maintains PagerDuty(PD.US) With Sell Rating, Raises Target Price to $8
    Market Newswire · 2026/7/22
  • Rating change
    Morgan Stanley Downgrades PagerDuty(PD.US) to Sell Rating, Maintains Target Price $9
    Market Newswire · 2026/7/22
  • Company notice
    LEADS BIOLABS-B: VOLUNTARY ANNOUNCEMENTLBL-024 (OPAMTISTOMIG, PD-L1/4-1BBBISPECIFIC ANTIBODY)GRANTED FAST TRACK DESIGNATION BY THE U.S. FDAFOR FIRST-LINE TREATMENT OF ADVANCEDBILIARY TRACT CANCER
    HKEX · 2026/10/12
  • Rating change
    Monness Maintains PagerDuty(PD.US) With Hold Rating
    Market Newswire · 2026/8/24
  • Rating change
    TD Cowen Maintains PagerDuty(PD.US) With Buy Rating, Raises Target Price to $13.5
    Market Newswire · 2026/8/26
  • Company notice
    Immutep Ltd: Fourth U.S. Patent Secured for Efti and PD-1 Combination
    ASX · 2026/7/14
  • Henlius Pharmaceuticals opened higher as its PD-L1/VEGF bispecific antibody initiated a Phase 2/3 clinical trial for first-line treatment of non-small cell lung cancer (NSCLC).
    Zhitong Finance · 2026/10/9
  • Company notice
    CSTONE PHARMA-B: VOLUNTARY ANNOUNCEMENT - CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY) RECEIVES U.S. FDA IND CLEARANCE FOR PHASE II CLINICAL TRIAL
    HKEX · 2026/2/16
  • Company notice
    QD PD B2803: PUBLICATION OF THE OFFERING CIRCULAR - QINGDAO PINGDU HOLDINGS GROUP CO., LTD. - U.S.$84,000,000 6.9 per cent. Social Bonds due 2028
    HKEX · 2025/3/12
  • Henlius Biopharma (02696.HK): Positive U.S. bridging clinical results for PD-1; significant potential for TCE quadruple antibody
    Tianfeng Securities · 2026/11/12
  • CSPC Pharma (01093.HK): Results from the Phase I/II clinical study of SYS6090 (JMT108), an anti-PD-1/IL-15 bifunctional fusion protein, as monotherapy for advanced solid tumors, were presented as a rapid oral presentation at the 2026 ESMO Congress.
    Gelonghui Finance · 2026/10/27
  • Company notice
    LEADS BIOLABS-B: VOLUNTARY ANNOUNCEMENT- LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA
    HKEX · 2026/1/14
  • Anker Innovations (300866): Q3 2026 revenue impacted by channel adjustments and PD timing mismatches; optimistic about improved growth in Q4 and long-term incremental gains in energy storage, security, maternal & infant care, and health businesses.
    Open Source Securities · 2026/10/31
  • Rating change
    Morgan Stanley Maintains PagerDuty(PD.US) With Sell Rating, Maintains Target Price $10
    Market Newswire · 2026/9/18
  • Rating change
    BofA Securities Maintains PagerDuty(PD.US) With Sell Rating, Raises Target Price to $11
    Market Newswire · 2026/10/23
  • Merck & Co.: Impressive data for sac-TMT in PD-L1-negative non-small cell lung cancer at ESMO 2026
    CSOP · 2026/10/26
  • CSPC Pharma (01093): Results from the Phase I/II clinical study of monotherapy with the anti-PD-1/IL-15 bispecific fusion protein SYS6090 (JMT108) in advanced solid tumors were presented as a rapid oral presentation at the 2026 ESMO Congress.
    Zhitong Finance · 2026/10/27
  • Rating change
    Truist Financial Maintains PagerDuty(PD.US) With Buy Rating, Raises Target Price to $11
    Market Newswire · 2026/7/9
  • Rating change
    Truist Financial Maintains PagerDuty(PD.US) With Buy Rating, Maintains Target Price $11
    Market Newswire · 2026/7/14
  • Crescent Biopharma Says Global Phase 1/2 APOLLO Trial Of CR-002, a PD-L1-Targeted ADC, On Track To Commence Dosing This Quarter; Initial Data Expected In H2 2027; Phase 1/2 Trial Of CR-003 (SKB105), An ITGB6-Targeted ADC, Ongoing In China; Initial...
    Benzinga · 2026/10/16

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:20 · For reference only, not investment advice and not tailored to your situation.

PagerDuty discussion 0 comments

Add a comment